Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
True. Hedge fund has enough $$$ to take the risk though. Deerfield Management probably forgot this one already...
The institutional investors didn't buy in at 20.00 and 25.00 dollars a share for nothing. Remember 89% of this stock is held by institutional investor and insiders. Very low float .
It doubled from the bottom already...think it will keep going? This low volume stocks are so easy to manipulated
This is something that may be good to listen to shortly.
Rodman & Renshaw 18th Annual Global Investment Conference
Date: Tuesday, September 13th
Location: The Lotte New York Palace Hotel, New York
Presentation Time: 10:25 AM EDT
Individuals may access a live webcast of the conference presentations on the Nivalis website at www.nivalis.com under "IR Calendar" in the "News / Events" section. A replay of the webcast will be available on this site for 90 days following the live event.
Great. Any news though?
Looks like it was a small pull back but today looks like it is turning north.
U R the man!!!
Good catch, run to $15
NEWS -- Nivalis Therapeutics to Present at Two Upcoming Investor Conferences
Date : 09/06/2016 @ 7:30AM
Source : GlobeNewswire Inc.
Stock : Nivalis Therapeutics, Inc. (MM) (NVLS)
Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today announced that Chief Executive Officer, Jon Congleton will present a corporate overview at Baird’s Global Healthcare Conference and the Rodman & Renshaw 18th Annual Global Investment Conference.
Details of the two presentations are as follows
Baird’s Global Healthcare Conference
Date: Thursday, September 8th
Location: The New York Palace, New York
Presentation Time: 10:50 AM EDT
Rodman & Renshaw 18th Annual Global Investment Conference
Date: Tuesday, September 13th
Location: The Lotte New York Palace Hotel, New York
Presentation Time: 10:25 AM EDT
Individuals may access a live webcast of the conference presentations on the Nivalis website at www.nivalis.com under "IR Calendar" in the "News / Events" section. A replay of the webcast will be available on this site for 90 days following the live event.
About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
Contacts:
Investor Relations
John Graziano
1-646-378-2942
mailto://jgraziano@troutgroup.com
Media Relations
Lindsay Rocco
1-862-596-1304
mailto://lrocco@elixirhealthpr.com
Which institution hold it? I'm betting on it too. $15 would be nice enough. It is definitely under the radar and Deerfield Management has a lot of it from $15...
50,000 shares bought today this is ready to rock ! Someone bought over a quarter of a million dollars worth of stock, this is ready to go to 20 dollars a share, low float and over 80% held by institutions and insiders .WOW ! And way under the radar.
NEWS -- Nivalis Therapeutics Announces Completion of Enrollment in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis
Date : 07/07/2016 @ 7:00AM
Source : GlobeNewswire Inc.
Stock : Nivalis Therapeutics Com USD0.001 (MM) (NVLS)
Study is Evaluating N91115 in Patients Homozygous for the F508del-CFTR Mutation and Being Treated with Orkambi™
Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today announced completion of enrollment, defined as the last patient enrolled receiving their first study dose, in the larger of the two Phase 2 clinical studies of N91115, a novel stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. In this study, N91115 is being evaluated for the treatment of CF patients, who have two copies of the F508del mutation, when added to Orkambi™ (lumacaftor/ivacaftor). A total of 138 patients have been enrolled at 46 sites in the U.S. and topline results are expected by the end of this year.
The Company also announced that the United States Adopted Names (USAN) Council has approved “cavosonstat” as the unique non-proprietary or generic name for N91115, which the Company will use going forward to refer to N91115.
“Completing enrollment in this Phase 2 study represents a critical milestone in our clinical development program for cavosonstat and moves us closer to our goal of bringing our novel stabilizer to people with CF,” said Jon Congleton, president and chief executive officer of Nivalis. “We would like to thank the study participants and their families, the clinical trial sites and the CF community for their continued commitment to this effort and we look forward to the topline results of this study by the end of this year.”
Cavosonstat works through a novel mechanism of action called S-nitrosoglutathione reductase (GSNOR) inhibition that is presumed to modulate the unstable and defective CFTR protein responsible for CF. GSNOR inhibition restores GSNO levels, thereby modifying the chaperones responsible for CFTR protein degradation. In preclinical testing, this stabilizing effect was shown to increase and prolong the function of the CFTR protein and may lead to an increase in net chloride secretion. This effect is both complementary and agnostic to other CFTR modulators, like Orkambi.
Study Design
The 16-week, double-blind, randomized, placebo-controlled, parallel group study is designed to investigate the efficacy and safety of two doses of cavosonstat, 200mg and 400mg, administered twice daily in adult patients with CF who are homozygous for the F508del-CFTR mutation and being treated with Orkambi™. The study includes a 4-week withdrawal and follow-up period once patients have completed 12-weeks of dosing. The primary clinical efficacy outcome will be the absolute change from baseline in percent predicted FEV1. For more information on this study, please visit ClinicalTrials.gov and reference Identifier NCT02589236.
About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical-stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
About Cavosonstat
Cavosonstat works through a novel mechanism of action called GSNOR inhibition that is presumed to modulate the unstable and defective CFTR protein responsible for CF. GSNOR inhibition restores GSNO levels thereby modifying the chaperones responsible for CFTR protein degradation. This stabilizing effect has been shown to increase and prolong the function of the CFTR chloride channel and increase net chloride secretion in preclinical experiments. Nivalis discovered and owns exclusive rights to cavosonstat in the United States (U.S.) and all other major markets, including U.S. composition of matter patent protection until at least 2031. Cavosonstat was granted Orphan Drug and Fast Track designations by the FDA earlier this year. Nivalis Therapeutics has completed clinical studies with cavosonstat, including a Phase 1a dose-escalation safety study in healthy volunteers, and a Phase 1b safety study in people with CF who have two copies of the F508del-CFTR mutation. In preclinical studies, cavosonstat has been shown to increase the function of F508del-CFTR, the mutant protein that is estimated to be present in approximately 86 percent of people with CF in the United States and Europe.
About Cystic Fibrosis
CF is a life-shortening genetic disease that affects an estimated 70,000 people worldwide, predominantly in the United States and Europe, according to the Cystic Fibrosis Foundation (www.cff.org). CF is characterized by a defect in the chloride channel known as the “cystic fibrosis transmembrane conductance regulator,” or CFTR, and is caused by mutations in the CFTR gene.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nivalis’ development plans and potential opportunities, statements regarding the timing of completion of and availability of topline clinical results, and expectations that early stage clinical trials are indicative of later stage clinical trial results or will result in an approved drug. These forward-looking statements are based on management’s current expectations of future events and involve substantial risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including that preclinical responses may not be predictive of clinical results, delays in the timing of regulatory filings and approvals, delays in the commercialization or availability of lumacaftor/ivacaftor, and other matters that could affect the completion of the clinical development and commercial potential of the company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Nivalis’ business in general, see the risk factors contained in the company’s annual report on Form 10-K filed with the Securities and Exchange Commission on March 8, 2016 and in other reports filed by Nivalis with the Securities and Exchange Commission. All information in this press release is as of the date of this release, and Nivalis undertakes no duty to update or revise this information unless required by law.
Contacts:
Investor Relations
John Graziano
1-646-378-2942
mailto://jgraziano@troutgroup.com
Media Relations
Lindsay Rocco
1-862-596-1304
mailto://lrocco@elixirhealthpr.com
NEWS -- Nivalis Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
Date : 07/06/2016 @ 4:05PM
Source : GlobeNewswire Inc.
Stock : Nivalis Therapeutics Com USD0.001 (MM) (NVLS)
Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today announced that Chief Executive Officer, Jon Congleton will present a corporate overview at Cantor Fitzgerald's 2nd Annual Healthcare Conference.
Details of the presentations are as follows:
Cantor Fitzgerald's 2nd Annual Healthcare Conference
Date: Tuesday, July 12th
Location: Le Parker Meridien, New York
Presentation Time: 1:30 PM EDT
Individuals may access a live webcast of the conference presentations on the Nivalis website at http://www.nivalis.com under "IR Calendar" in the "News / Events" section. A replay of the webcast will be available on this site for 90 days following the live event.
About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical-stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
Contacts:
Investor Relations
John Graziano
1-646-378-2942
mailto://jgraziano@troutgroup.com
Media Relations
Lindsay Rocco
1-862-596-1304
mailto://lrocco@elixirhealthpr.com
NEWS -- Nivalis Therapeutics to Present at the JMP Securities Life Sciences Conference
Date : 06/15/2016 @ 7:00AM
Source : GlobeNewswire Inc.
Stock : Nivalis Therapeutics Com USD0.001 (MM) (NVLS)
Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today announced that Chief Executive Officer, Jon Congleton will present a corporate overview at the JMP Securities Life Sciences Conference.
Details of the presentations are as follows:
JMP Securities Life Sciences Conference
Date: Wednesday, June 22nd
Location: The St. Regis New York, New York
Presentation Time: 12:30 PM EDT
Individuals may access a live webcast of the conference presentations on the Nivalis website at http://www.nivalis.com under "IR Calendar" in the "News / Events" section. A replay of the webcast will be available on this site for 90 days following the live event.
About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical-stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
Contacts:
Investor Relations
John Graziano
1-646-378-2942
mailto://jgraziano@troutgroup.com
Media Relations
Lindsay Rocco
1-862-596-1304
mailto://lrocco@elixirhealthpr.com
NEWS -- Nivalis Therapeutics to Present at the Jefferies 2016 Healthcare Conference
Date : 06/01/2016 @ 7:00AM
Source : GlobeNewswire Inc.
Stock : Nivalis Therapeutics Com USD0.001 (MM) (NVLS)
Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today announced that Chief Executive Officer, Jon Congleton will present a corporate overview at the Jefferies 2016 Healthcare Conference.
Details of the presentations are as follows:
Jefferies 2016 Healthcare Conference
Date: Tuesday, June 7th
Location: Grand Hyatt, New York
Presentation Time: 9:00 AM EDT
Individuals may access a live webcast of the conference presentations on the Nivalis website at http://www.nivalis.com under "IR Calendar" in the "News / Events" section. A replay of the webcast will be available on this site for 90 days following the live event.
About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical-stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
Contacts:
Investor Relations
John Graziano
1-646-378-2942
mailto://jgraziano@troutgroup.com
Media Relations
Lindsay Rocco
1-862-596-1304
mailto://lrocco@elixirhealthpr.com
NEWS -- Nivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment of Cystic Fibrosis
Study to Evaluate N91115 in Patients Heterozygous for F508del-CFTR and a Gating Mutation
Data Expected in the First Half of 2017
BOULDER, Colo., May 16, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today announced the first patient was dosed in a second Phase 2 clinical study of its lead investigational drug, N91115, a stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This proof-of-concept study will evaluate the effect of N91115 as add-on therapy to Kalydeco™ (ivacaftor) in adult patients who have one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein.
“The initiation of our second Phase 2 study sets us on the path to demonstrate that a multi-mechanism approach that includes N91115 as a novel stabilizer of the CFTR protein may help CF patients already being treated with Kalydeco achieve better clinical outcomes,” said Jon Congleton, president and chief executive officer of Nivalis. “We hope to observe a positive impact of N91115 on lung function in this trial, and add to the important research targeted at increasing treatment options that address F508del, the most common mutation of the CFTR gene. We look forward to the results of this study in the first half of 2017.”
N91115 works through a novel mechanism of action called S-nitrosoglutathione reductase (GSNOR) inhibition that is presumed to modulate the unstable and defective CFTR protein responsible for CF. GSNOR inhibition restores GSNO levels, thereby modifying the chaperones responsible for CFTR protein degradation. In preclinical testing, this stabilizing effect was shown to increase and prolong the function of the CFTR protein and may lead to an increase in net chloride secretion. This effect is both complementary and agnostic to other CFTR modulators, like Orkambi™.
Study Design
The 12-week, double-blind, randomized, placebo-controlled, parallel group study is designed to investigate the efficacy and safety of 400mg of N91115 administered twice daily in adult patients with CF who are heterozygous for F508del-CFTR and a gating mutation that is approved for treatment with Kalydeco. This multicenter study will randomize approximately 20 CF patients to either N91115 with Kalydeco or placebo with Kalydeco.
The primary efficacy endpoint is the within group absolute change from baseline in percent predicted FEV1 in the N91115 treatment group. The expected completion date is the first half of 2017. For more information on this study, please visit http://ClinicalTrials.gov and reference Identifier: NCT02724527.N91115.
About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical-stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
About N91115
N91115 works through a novel mechanism of action called GSNOR inhibition that is presumed to modulate the unstable and defective CFTR protein responsible for CF. GSNOR inhibition restores GSNO levels thereby modifying the chaperones responsible for CFTR protein degradation. This stabilizing effect has been shown to increase and prolong the function of the CFTR chloride channel and increase net chloride secretion in preclinical experiments. Nivalis discovered and owns exclusive rights to N91115 in the United States (U.S.) and all other major markets, including U.S. composition of matter patent protection until at least 2031. N91115 was granted Orphan Drug and Fast Track designations by the FDA earlier this year. Nivalis Therapeutics has completed clinical studies with N91115, including a Phase 1a dose-escalation safety study in healthy volunteers, and a Phase 1b safety study in people with CF who have two copies of the F508del-CFTR mutation. In preclinical studies, N91115 has been shown to increase the function of F508del-CFTR, the mutant protein that is estimated to be present in approximately 86 percent of people with CF in the United States and Europe.
About Cystic Fibrosis
CF is a life-shortening genetic disease that affects an estimated 70,000 people worldwide, predominantly in the United States and Europe, according to the Cystic Fibrosis Foundation (www.cff.org). CF is characterized by a defect in the chloride channel known as the “cystic fibrosis transmembrane conductance regulator,” or CFTR, and is caused by mutations in the CFTR gene.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nivalis’ development plans and potential opportunities, statements regarding the timing of completion of the second Phase 2 trial, and expectations that early stage clinical trials are indicative of later stage clinical trial results or will result in an approved drug. These forward-looking statements are based on management’s current expectations of future events and involve substantial risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including that preclinical responses may not be predictive of clinical results, the risk that site initiation and patient enrollment for our clinical trials may take longer than expected, delays in the timing of regulatory filings and approvals, delays in the commercialization or availability of lumacaftor/ivacaftor, and other matters that could affect the completion of the clinical development and commercial potential of the company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Nivalis’ business in general, see the risk factors contained in the company’s annual report on Form 10-K filed with the Securities and Exchange Commission on March 8, 2016 and in other reports filed by Nivalis with the Securities and Exchange Commission. All information in this press release is as of the date of this release, and Nivalis undertakes no duty to update or revise this information unless required by law.
Contact:
Investor Relations
John Graziano
1-646-378-2942
mailto://jgraziano@troutgroup.com
Media Relations
Lindsay Rocco
1-862-596-1304
mailto://lrocco@elixirhealthpr.com
NEWS -- Nivalis Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BOULDER, Colo., April 22, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today announced the grant to Dr. David Rodman, the Company’s newly appointed chief medical officer and executive vice president of discovery, of a non-statutory stock option to purchase an aggregate of 108,333 shares of its common stock and of restricted stock units representing 216,667 shares of its common stock. The inducement grants were approved by Nivalis’ Compensation Committee and were made as an inducement material to Dr. Rodman’s acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
The stock option has an exercise price equal to $4.68, which was the closing price of Nivalis’ common stock on April 18, 2016, the grant date of the awards. The stock option has a term of 10 years and vests over four years, with 25% of the original number of option shares vesting on the first anniversary of the grant date and the remaining shares vesting in equal monthly installments over the 36-month period thereafter. The restricted stock units vest over three years in equal quarterly installments, commencing on the first day of the calendar quarter following the grant date. Vesting of the awards is subject to Dr. Rodman’s continued service with the Company through the applicable vesting dates. The vesting of the stock option and restricted stock units accelerates in full upon Dr. Rodman’s death or if his employment is terminated other than for cause by the Company or by him for certain “good reason” events specified in the award agreements within 12 months of a change in control of the Company. In addition, if Dr. Rodman’s employment agreement is terminated other than for cause by the Company prior to expiration of its term, any unvested options and restricted stock units scheduled to vest in the 12 months following the termination date will accelerate and become vested.
About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary GSNOR inhibitor portfolio to develop therapeutics for other diseases.
Contacts:
Investor Relations
John Graziano
1-646-378-2942
mailto://jgraziano@troutgroup.com
Media Relations
Lindsay Rocco
1-862-596-1304
mailto://lrocco@elixirhealthpr.com
NEWS -- Nivalis Therapeutics Appoints David Rodman, MD as Chief Medical Officer and Executive Vice President of Discovery
Date : 04/18/2016 @ 7:00AM
Source : GlobeNewswire Inc.
Stock : Nivalis Therapeutics Com USD0.001 (MM) (NVLS)
Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today announced the appointment of David Rodman, MD as chief medical officer and executive vice president of discovery.
Dr. Rodman most recently served as chief medical officer and executive vice president, research and development at miRagen Therapeutics. Prior to his role at miRagen, he served as vice president, head of respiratory clinical development at Vertex Pharmaceuticals Inc., where he led teams in the development of Vertex’s cystic fibrosis programs, including Orkambi. These efforts led to Breakthrough Therapy Designation from the U.S. Food and Drug Administration as well as multiple successful regulatory applications globally.
"I am excited to be joining the Nivalis team at this pivotal time in the Company's evolution,” said David Rodman. “I see significant opportunity in the Company’s S-nitrosoglutathione reductase (GSNOR) inhibition technology and look forward to helping Nivalis deliver on its mission to bring innovative solutions that improve the lives of people with CF.”
Dr. Rodman will lead the discovery and clinical development strategy and operations for Nivalis, including advancement of N91115, the Company’s lead investigational drug and first-in-class stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
“We are thrilled to welcome David to the Nivalis team. He brings extensive expertise in clinical research and development along with a deep understanding of the unique needs of the CF community,” said Jon Congleton, president and chief executive officer of Nivalis. “His leadership experience in both industry and clinical settings, coupled with his talent in bringing innovative respiratory products to market, will be invaluable as we continue to develop and expand our product pipeline.”
Prior to Vertex, Dr. Rodman held roles of increasing responsibility at the Novartis Institutes for Biomedical Research. He has also served in several academic leadership positions, including director of the Center for Genetic Lung Disease at the University of Colorado School of Medicine, director of the Cystic Fibrosis Center at National Jewish Medical and Research Center and director of the Adult Cystic Fibrosis Program at the University of Colorado Health Sciences Center.
About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary GSNOR inhibitor portfolio to develop therapeutics for other diseases.
About N91115
N91115 works through a novel mechanism of action called GSNOR inhibition that is presumed to modulate the unstable and defective CFTR protein responsible for CF. GSNOR inhibition restores GSNO levels thereby modifying the chaperones responsible for CFTR protein degradation. This stabilizing effect has been shown to increase and prolong the function of the CFTR chloride channel and increase net chloride secretion in preclinical experiments. Nivalis discovered and owns exclusive rights to N91115 in the United States (U.S.) and all other major markets, including U.S. composition of matter patent protection until at least 2031. N91115 was granted Orphan Drug and Fast Track designations by the U.S. FDA earlier this year.
About Cystic Fibrosis
CF is a life-shortening genetic disease that affects an estimated 70,000 people worldwide, predominately in the United States and Europe, according to the Cystic Fibrosis Foundation (www.cff.org). CF is characterized by a defect in the chloride channel known as the “cystic fibrosis transmembrane conductance regulator,” or CFTR, and is caused by mutations in the CFTR gene.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nivalis’ development plans and potential opportunities and expectations that early stage clinical trials are indicative of later stage clinical trial results or will result in an approved drug. These forward-looking statements are based on management’s current expectations of future events and involve substantial risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including that preclinical responses may not be predictive of clinical results, the risk that site initiation and patient enrollment for our clinical trials may take longer than expected, delays in the timing of regulatory filings and approvals, delays in the commercialization or availability of lumacaftor/ivacaftor, and other matters that could affect the completion of the clinical development and commercial potential of the company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Nivalis’ business in general, see the risk factors contained in the company’s annual report on Form 10-K filed with the Securities and Exchange Commission on March 8, 2016 and in other reports filed by Nivalis with the Securities and Exchange Commission. All information in this press release is as of the date of this release, and Nivalis undertakes no duty to update or revise this information unless required by law.
Contacts:
Investor Relations
John Graziano
1-646-378-2942
mailto://jgraziano@troutgroup.com
Media Relations
Lindsay Rocco
1-862-596-1304
mailto://lrocco@elixirhealthpr.com
Over 80% held by institutions and insiders , this should double in a few month.
About 700 thousand tradable share and more and more investors are getting in and holding strong ,I for one predict a buy out for 80 dollars a share lowball .
No shares to trade way over sold and short, 60 million in the bank this should be around 25 dollars a share ,what is not to like , easy 5 to 10 times one will make money here .
NEWS -- Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic Fibrosis
Date : 04/05/2016 @ 8:00AM
Source : GlobeNewswire Inc.
Stock : Nivalis Therapeutics Com USD0.001 (MM) (NVLS)
Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today announced they have reached the halfway point in dosing of the 135 patient Phase 2 clinical trial evaluating N91115, the Company’s lead investigational drug and first-in-class stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
“We are encouraged by the progress we have made with patient enrollment in this trial and by the interest expressed by the cystic fibrosis community in a multi-mechanism approach that includes N91115 as a stabilizer of the CFTR protein,” said Jon Congleton, president and chief executive officer of Nivalis. “We are grateful to the investigators, research staff, and especially the patients who have participated, for enabling us to remain on track to report results in the fourth quarter of this year.”
The Phase 2 study is designed to investigate the efficacy and safety of two doses of N91115, 200mg and 400mg, administered twice daily versus placebo in 135 adult patients with CF who are homozygous for the F508del-CFTR mutation and being treated with Orkambi™.
N91115 works through a novel mechanism of action called S-nitrosoglutathione reductase (GSNOR) inhibition that is presumed to modulate the unstable and defective CFTR protein responsible for CF. This effect is expected to be both complementary and agnostic to other CFTR modulators, like Orkambi™.
The Company continues to expect to report results from the study in the fourth quarter of this year. More information on this Phase 2 study is available on http://ClinicalTrials.gov, reference Identifier NCT02589236.N91115.
About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary GSNOR inhibitor portfolio to develop therapeutics for other diseases.
About N91115
N91115 works through a novel mechanism of action called GSNOR inhibition that is presumed to modulate the unstable and defective CFTR protein responsible for CF. GSNOR inhibition restores GSNO levels thereby modifying the chaperones responsible for CFTR protein degradation. This stabilizing effect has been shown to increase and prolong the function of the CFTR chloride channel and increase net chloride secretion in preclinical experiments. Nivalis discovered and owns exclusive rights to N91115 in the United States (U.S.) and all other major markets, including U.S. composition of matter patent protection until at least 2031. N91115 was granted Orphan Drug and Fast Track designations by the U.S. FDA earlier this year.
About Cystic Fibrosis
CF is a life-shortening genetic disease that affects an estimated 70,000 people worldwide, predominately in the United States and Europe, according to the Cystic Fibrosis Foundation (www.cff.org). CF is characterized by a defect in the chloride channel known as the “cystic fibrosis transmembrane conductance regulator,” or CFTR, and is caused by mutations in the CFTR gene.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nivalis’ development plans and potential opportunities, statements regarding completion of enrollment in the ongoing Phase 2 clinical trial and the timing of the release of results of that trial, and expectations that early stage clinical trials are indicative of later stage clinical trial results or will result in an approved drug. These forward-looking statements are based on management’s current expectations of future events and involve substantial risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including that preclinical responses may not be predictive of clinical results, the risk that site initiation and patient enrollment for our clinical trials may take longer than expected, delays in the timing of regulatory filings and approvals, delays in the commercialization or availability of lumacaftor/ivacaftor, and other matters that could affect the completion of the clinical development and commercial potential of the company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Nivalis’ business in general, see the risk factors contained in the company’s annual report on Form 10-K filed with the Securities and Exchange Commission on March 8, 2016 and in other reports filed by Nivalis with the Securities and Exchange Commission. All information in this press release is as of the date of this release, and Nivalis undertakes no duty to update or revise this information unless required by law.
Contacts:
Investor Relations
John Graziano
1-646-378-2942
mailto://jgraziano@troutgroup.com
Media Relations
Lindsay Rocco
1-862-596-1304
mailto://lrocco@elixirhealthpr.com
NEWS -- Nivalis Therapeutics Expands N91115 Clinical Development Program in Cystic Fibrosis
Higher-dose arm initiated in ongoing Phase 2 study following safety review by independent Data Monitoring Committee
New Phase 2 study planned for patients who have one copy of the F508del-mutation and a second gating mutation
BOULDER, Colo., March 07, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today announced the expansion of their clinical development plan for N91115, the Company’s lead investigational drug and first-in-class stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
An independent Data Monitoring Committee (DMC) has completed its review of the interim safety data from the Company’s ongoing Phase 2 study evaluating the efficacy and safety of N91115 in adult patients who have two copies of the F508del mutation and are being treated with Orkambi™. The DMC concluded that there were no safety concerns and the study may proceed with enrolling and randomizing patients in a higher (400mg) dose cohort of N91115. The study initially started with 200mg BID or placebo cohorts in late 2015. The 12-week, double-blind, randomized, placebo-controlled, parallel group study is designed to compare two doses of N91115, 200mg and 400mg, administered twice daily when added to Orkambi. More information on this Phase 2 study is available on http://ClinicalTrials.gov, reference Identifier NCT02589236.N91115.
Nivalis will also initiate a new trial to further evaluate the effect of N91115 in patients who have one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein. The Company will begin a Phase 2, proof-of-concept study to evaluate the efficacy and safety of N91115 in adult patients who have these mutations and who are being treated with Kalydeco™ (ivacaftor). This multicenter study is planned to begin enrollment in the United States during the second quarter of 2016. The study will randomize approximately 20 CF patients to either N91115 with Kalydeco or placebo with Kalydeco. The primary efficacy endpoint is the absolute change from baseline in ppFEV1 in the N91115 treatment group.
“Enrollment of the ongoing Phase 2 study has been encouraging, and we are pleased that the DMC has validated the initial clinical safety of N91115 with its recent approval of the higher dose arm,” said Jon Congleton, president and chief executive officer of Nivalis. “We also look forward to initiating our second Phase 2 study which aims to show the additional benefit of N91115 in people with different CF mutations, as we believe multiple mechanisms of action will be required to fully achieve optimal clinical outcomes for patients living with CF.”
N91115 works through a novel mechanism of action called S-nitrosoglutathione reductase (GSNOR) inhibition that is presumed to modulate the unstable and defective CFTR protein responsible for CF. GSNOR inhibition restores GSNO levels, thereby modifying the chaperones responsible for CFTR protein degradation. In preclinical testing, this stabilizing effect was shown to increase and prolong the function of the CFTR protein and may lead to an increase in net chloride secretion. This effect is expected to be both complementary and agnostic to other CFTR modulators, like Orkambi™.
About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary GSNOR inhibitor portfolio to develop therapeutics for other diseases.
About N91115
N91115 works through a novel mechanism of action called GSNOR inhibition that is presumed to modulate the unstable and defective CFTR protein responsible for CF. GSNOR inhibition restores GSNO levels thereby modifying the chaperones responsible for CFTR protein degradation. This stabilizing effect increases and prolongs the function of the CFTR chloride channel and leads to an increase in net chloride secretion. Nivalis discovered and owns exclusive rights to N91115 in the United States (U.S.) and all other major markets, including U.S. composition of matter patent protection until at least 2031. N91115 was granted Orphan Drug and Fast Track designations by the U.S. FDA earlier this year.
About Cystic Fibrosis
CF is a life-shortening genetic disease that affects an estimated 70,000 people worldwide, predominately in the United States and Europe, according to the Cystic Fibrosis Foundation (http://www.cff.org). CF is characterized by a defect in the chloride channel known as the “cystic fibrosis transmembrane conductance regulator,” or CFTR, and is caused by mutations in the CFTR gene.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nivalis’ development plans and potential opportunities, statements regarding the timing of starting a new Phase 2 trial and enrollment in the ongoing Phase 2 clinical trial, and expectations that early stage clinical trials are indicative of later stage clinical trial results or will result in an approved drug. These forward-looking statements are based on management’s current expectations of future events and involve substantial risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including that preclinical responses may not be predictive of clinical results, the risk that site initiation and patient enrollment for our clinical trials may take longer than expected, delays in the timing of regulatory filings and approvals, delays in the commercialization or availability of lumacaftor/ivacaftor, and other matters that could affect the completion of the clinical development and commercial potential of the company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Nivalis’ business in general, see the risk factors contained in the company’s prospectus filed with the Securities and Exchange Commission on June 17, 2015, in the company’s most recent quarterly report on Form 10-Q and in its other reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of this release, and Nivalis undertakes no duty to update or revise this information unless required by law.
Contacts:
Investor Relations
John Graziano
1-646-378-2942
mailto://jgraziano@troutgroup.com
Media Relations
Lindsay Rocco
1-862-596-1304
mailto://lrocco@elixirhealthpr.com
$NVLS recent news/filings
bearish 8.40
## source: finance.yahoo.com
Tue, 10 Nov 2015 12:16:19 GMT ~ Nivalis Therapeutics to Present at the Stifel Healthcare Conference 2015
[at noodls] - BOULDER, Colo., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today announced ...
read full: http://www.noodls.com/view/7C41D206440B9E8089E3C9773EDACD01AF095209
*********************************************************
Tue, 10 Nov 2015 12:00:00 GMT ~ Nivalis Therapeutics to Present at the Stifel Healthcare Conference 2015
[GlobeNewswire] - BOULDER, Colo., Nov. 10, 2015-- Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company focused on treating people with cystic fibrosis, today announced that Chief Executive Officer Jon Congleton ...
read full: http://finance.yahoo.com/news/nivalis-therapeutics-present-stifel-healthcare-120000337.html
*********************************************************
Tue, 03 Nov 2015 22:04:44 GMT ~ NIVALIS THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
read full: http://biz.yahoo.com/e/151103/nvls10-q.html
*********************************************************
Mon, 02 Nov 2015 22:03:20 GMT ~ NIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
read full: http://biz.yahoo.com/e/151102/nvls8-k.html
*********************************************************
Mon, 02 Nov 2015 21:26:07 GMT ~ Nivalis Therapeutics Reports Third Quarter and Nine-Month Financial Results for 2015
[at noodls] - - N91115 Phase 1b Data Recently Presented at North American Cystic Fibrosis Conference - Phase 2 Study on Track to Enroll First Patient in Fourth Quarter BOULDER, Colo., Nov. 02, 2015 (GLOBE NEWSWIRE) ...
read full: http://www.noodls.com/view/76ED010232277410F4E54F5B1D96033DFF90C46E
*********************************************************
$NVLS charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$NVLS company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/NVLS/company-info
Ticker: $NVLS
OTC Market Place: Not Available
CIK code: not found
Company name: Nivalis Therapeutics, Inc.
Incorporated In:
$NVLS share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$NVLS extra dd links
Company name: Nivalis Therapeutics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NVLS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NVLS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NVLS+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NVLS/news - http://finance.yahoo.com/q/h?s=NVLS+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NVLS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NVLS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NVLS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NVLS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Nivalis+Therapeutics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Nivalis+Therapeutics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Nivalis+Therapeutics%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NVLS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NVLS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NVLS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NVLS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NVLS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NVLS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NVLS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NVLS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NVLS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NVLS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NVLS+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NVLS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NVLS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NVLS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NVLS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NVLS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NVLS/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NVLS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NVLS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NVLS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NVLS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NVLS
$NVLS DD Notes ~ http://www.ddnotesmaker.com/NVLS
Novellus to be purchased by Lam Research (LRCX); Based on the closing price of LRCX's stock on Dec 14, 2011, the transaction values NVLS at a price of $44.42/common share (NVLS) 34.70 -0.61 : LRCX announced that it has entered into a definitive merger agreement to acquire Novellus Systems (NVLS) in an all-stock transaction valued at ~$3.3 billion. The combined enterprise, which will retain the name of Lam Research Corp., will be a semiconductor equipment co with a broad portfolio of market-leading products and multiple opportunities to drive value creation through significant revenue and cost synergies. Total cost synergies are expected to be ~$100 million on an annualized basis by the fourth quarter of 2013. In addition, Lam announced a $1.6 billion common stock repurchase program. This new program, which replaces Lam's existing share repurchase program, is targeted to be executed over the 12 months following the close of the transaction. Lam expects the transaction to be accretive to its non-GAAP earnings within one year after transaction close. Under the terms of the agreement, Novellus stockholders will receive 1.125 shares of Lam Research common stock for each share of Novellus that they own, in a tax-free exchange. Based on the closing price of Lam's stock on December 14, 2011, the transaction values Novellus at a price of $44.42 per common share. Upon closing, Lam and Novellus stockholders will own approximately 59 percent and 41 percent, respectively, of the combined company.
Novellus Systems Inc. (NVLS): CEO Richard Hill Bought 10,000 Shares
Novellus Systems, Inc. (NVLS) engages in the manufacture, marketing, and servicing of semiconductor equipment for thin film deposition, surface preparation, and chemical mechanical planarization. The company shares prices have dropped nearly 10% its value year to date. Due to lower sales, Novellus cut their first quarter earnings 71% to $15.5 million or $0.15 a share compared to $53.8 million or $0.42 a year ago. Revenue declined 21% to $314.7 million. The company expects slower business for the rest of the year.
Bruce Sherman owns 9,324,671 shares since the last quarter of 2007.
CEO Richard Hill bought 10,000 shares on 4/25/08 at $21.82, while officers sold shares at $24.50 to $26.70 in the past two quarters: EVP Jeffrey Benzing sold 4,498 shares; Technical Officer Fusen Ernie Chen sold 4,397 shares; SVP Martin J. Collins sold 1,607 shares; and Director J. David Litster sold 500 shares.
Novellus Systems Inc. has a market cap of $2.23 billion; its shares were traded at around $22.96 with a P/E ratio of 15.12 and P/S ratio of 1.48.
http://www.gurufocus.com/news.php?id=26597
Novellus First Quarter 2008 Earnings Conference Call
Scheduled to start Mon, Apr 21, 2008, 4:30 pm Eastern
http://biz.yahoo.com/cc/0/92380.html
Novellus Ships 100th 300 mm Tool to the China Market
Monday March 17, 8:45 am ET
Shipment to Wuhan Xinxin Semiconductor Highlights Growth of Advanced Technology in the Region
SHANGHAI, China, March 17 /PRNewswire-FirstCall/ -- Novellus Systems today announced it has shipped its 100th 300 mm tool into China, marking a major milestone in its growth in the region. The 100th tool -- a VECTOR Express(TM) CVD platform -- has been selected by Wuhan Xinxin Semiconductor Manufacturing Corporation for its new state-of-the-art manufacturing facility in Wuhan, China, which is operated and managed by Semiconductor Manufacturing International Corporation (SMIC).
Novellus has been an active participant in the growth of semiconductor manufacturing in China -- with installations of all its major 200 mm and 300 mm product lines among Chinese customers. According to SEMI's estimate, China will experience continued growth as processes with 180nm to 90nm feature sizes become mainstream over the next three years. At the same time, 300 mm tools will dominate spending in the new equipment market.* The Wuhan fab is poised to be part of this growth, as one of the largest and most advanced foundries in China.
"Fabs in China that are ramping up their 300 mm facilities are looking for high-productivity tools that will give them the maximum return on their investment," said Tom Caulfield, executive vice president of sales, marketing and customer service at Novellus. "We are very pleased to be working with Wuhan Xinxin Semiconductor to provide the efficiencies, economics and performance they require."
"Wuhan Xinxin Semiconductor is the first 300 mm fab in central China," said John Liu, vice president of the Wuhan project at SMIC. "Continued improvements in productivity are critical in delivering advanced technologies. Novellus' products, such as the production-proven VECTOR Express, are instrumental to achieving our goal."
*"China Semiconductor Wafer Fab and Foundry Outlook (2007-2008)," SEMI.
About Novellus:
Novellus Systems, Inc. (Nasdaq: NVLS - News) is a leading provider of advanced process equipment for the global semiconductor industry. The company's products deliver value to customers by providing innovative technology backed by trusted productivity. An S&P 500 company, Novellus is headquartered in San Jose, Calif. with subsidiary offices across the globe. For more information, please visit http://www.novellus.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that (i) China will experience continued growth as processes with 180nm to 90nm feature sizes become mainstream over the next three years; (ii) our belief that as China continues to experience continued growth, 300 mm tools will dominate spending in the new equipment market; (iii) our belief that the Wuhan fab is poised to be part of this growth as one of the largest and most advanced foundries in China and (iv) our belief that our products are instrumental in achieving SMIC's goals. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those contemplated by the forward-looking statements. Such risks and uncertainties include, but are not limited to, the difficulties in accurately forecasting the growth of the semiconductor market in China, the introduction of competitive products that affect the size and brand of the tools purchased by consumers, and unforeseen disruptions in manufacturing and production, as well as other risks indicated in our filings with the Securities and Exchange Commission (SEC). For more details, please refer to our SEC filings and the amendments thereto, including our Annual Report on Form 10-K for the year ended December 31, 2007, and our Current Reports on Form 8-K. Forward-looking statements are made and based on information available to us on the date of this press release, and we assume no obligation to update them.
VECTOR Express is a trademark of Novellus Systems, Inc.
Source: Novellus Systems, Inc.
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
83
|
Created
|
04/04/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |